Last reviewed · How we verify
Treatment Period(Placebo)
Treatment Period(Placebo) is a SGLT2 inhibitor Small molecule drug developed by JW Pharmaceutical. It is currently in Phase 3 development for Type 2 diabetes, Heart failure. Also known as: C2022+C2203.
This drug works by inhibiting the activity of a specific enzyme.
This drug works by inhibiting the activity of a specific enzyme. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Treatment Period(Placebo) |
|---|---|
| Also known as | C2022+C2203 |
| Sponsor | JW Pharmaceutical |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
The drug's mechanism of action involves targeting a key enzyme in the body, which plays a crucial role in the development of the disease. By inhibiting this enzyme, the drug helps to reduce the symptoms and progression of the disease.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of IY-828026 in Healthy Volunteers (PHASE1)
- Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) (PHASE2)
- Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis (PHASE1, PHASE2)
- A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (PHASE3)
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) (PHASE3)
- A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (PHASE2, PHASE3)
- Repeated Bilateral Greater Occipital Nerve Blockade in Chronic Migraine and Chronic Tension-Type Headache (NA)
- A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment Period(Placebo) CI brief — competitive landscape report
- Treatment Period(Placebo) updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI
Frequently asked questions about Treatment Period(Placebo)
What is Treatment Period(Placebo)?
How does Treatment Period(Placebo) work?
What is Treatment Period(Placebo) used for?
Who makes Treatment Period(Placebo)?
Is Treatment Period(Placebo) also known as anything else?
What drug class is Treatment Period(Placebo) in?
What development phase is Treatment Period(Placebo) in?
What are the side effects of Treatment Period(Placebo)?
What does Treatment Period(Placebo) target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: JW Pharmaceutical — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
- Indication: Drugs for Heart failure
- Also known as: C2022+C2203
- Compare: Treatment Period(Placebo) vs similar drugs
- Pricing: Treatment Period(Placebo) cost, discount & access